SCHEMBL6776483

SCHEMBL6776483

CNC(CCCC#Cc1cc2ncnc(Oc3ccc(F)cc3Br)c2cc1OC)NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.39
HDAC3 O15379 2/20 0.38
HDAC4 P56524 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC7 Q8WUI4 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC10 Q969S8 2/20 0.38
HDAC11 Q96DB2 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC9 Q9UKV0 2/20 0.38
HDAC5 Q9UQL6 2/20 0.38
KDR P35968 7/20 0.36
MET P08581 5/20 0.35
FLT3 P36888 1/20 0.35
EGFR P00533 2/20 0.35
BRAF P15056 3/20 0.35
RAF1 P04049 1/20 0.34
AXL P30530 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylamine SCHEMBL6776480 0.85 AXL (0.41) TRPA1HDAC3HDAC4HDAC1HDAC7
SCHEMBL6776188 0.82 MAP4K4 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6776474 0.82 AXL (0.40) TRPA1KDRMETFLT3EGFR
SCHEMBL6776477 0.77 TRPA1 (0.40) TRPA1HDAC3HDAC4HDAC1HDAC7
SCHEMBL6780346 0.76 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4422009 0.73 TRPA1 (0.52) TRPA1KDRMETEGFR
SCHEMBL4427782 0.73 KDR (0.45) TRPA1KDRMETFLT3EGFR
SCHEMBL4416517 0.72 KDM4E (0.43) TRPA1KDRMETFLT3EGFR
SCHEMBL4418189 0.72 TRPA1 (0.43) TRPA1HDAC3HDAC4HDAC1HDAC7
SCHEMBL4686840 0.71 TRPA1 (0.49) TRPA1KDRMETEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6806274-B1 IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS ASTRAZENECA UK LIMITED (GB) 2004-10-19 US disclosed